Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
Around 12% of hereditary disease-causing mutations are in-frame nonsense mutations. The expression of genes containing nonsense mutations potentially leads to the production of truncated proteins with residual or virtually no function. However, the translation of transcripts containing premature sto...
Main Author: | Sylwia Michorowska |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/785 |
Similar Items
-
Functional recovery of a novel knockin mouse model of dysferlinopathy by readthrough of nonsense mutation
by: Kyowon Seo, et al.
Published: (2021-06-01) -
Caffeine boosts Ataluren's readthrough activity
by: Laura Lentini, et al.
Published: (2019-06-01) -
Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs)
by: Ambra Campofelice, et al.
Published: (2019-07-01) -
Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency
by: Jonathan Frew, et al.
Published: (2020-03-01) -
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
by: Maciej Dabrowski, et al.
Published: (2018-05-01)